Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
QDEL
QuidelOrtho Corporation
QuidelOrtho directly develops diagnostic instruments and platforms (including molecular diagnostics platforms) used in labs, aligning with Diagnostic Equipment.
|
$863.41M |
$12.69
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$861.16M |
$27.64
+6.04%
|
|
MATW
Matthews International Corporation
Memorialization segment includes embalming chemicals and funeral supplies (memorialization products).
|
$848.12M |
$27.54
+2.23%
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$842.33M |
$9.69
+8.33%
|
|
TALK
Talkspace, Inc.
Talkspace is a behavioral health services provider delivering therapy to patients and payer networks.
|
$835.66M |
$5.00
+3.52%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$816.68M |
$4.80
-1.74%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$788.99M |
$5.68
+0.98%
|
|
CBLL
CeriBell, Inc.
Ceribell's core product is a point-of-care diagnostic EEG system (diagnostic equipment).
|
$786.06M |
$21.18
+2.12%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$780.30M |
$8.12
+2.78%
|
|
CLB
Core Laboratories N.V.
CLB provides laboratory testing and advisory services via proprietary tracers and reservoir analysis capabilities.
|
$768.30M |
$16.51
-2.42%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$764.86M |
$6.48
-0.31%
|
|
MEG
Montrose Environmental Group, Inc.
Laboratory testing and advisory services as part of Montrose's measurement and analysis offerings.
|
$764.35M |
$21.61
+3.50%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$747.36M |
$13.12
+4.88%
|
|
NUTX
Nutex Health, Inc.
Nutex Health operates micro-hospitals and provides hospital services including acute inpatient care and emergency/observation services.
|
$746.65M |
$105.59
+3.76%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$743.55M |
$5.24
+6.19%
|
|
CSTL
Castle Biosciences, Inc.
Castle Biosciences provides oncology biomarker diagnostics (DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher BE) using gene expression profiling and spatial omics, aligning with Biotech - Oncology.
|
$731.18M |
$25.05
+2.00%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$721.78M |
$21.34
+3.54%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$720.67M |
$4.42
+2.19%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$709.95M |
$12.56
-0.16%
|
|
VPG
Vishay Precision Group, Inc.
Medical infusion pump design win indicates participation in the Medical Devices & Biometrics market.
|
$706.71M |
$53.09
+3.34%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$706.47M |
$10.97
-0.23%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$703.31M |
$2.30
|
|
EHAB
Enhabit, Inc.
EHAB's core operations are the provision of home health and hospice services directly to patients.
|
$694.33M |
$13.73
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$687.75M |
$3.81
+3.81%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$686.46M |
$89.61
+1.08%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$679.56M |
$1.89
+2.72%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$672.37M |
$8.61
+2.62%
|
|
ETON
Eton Pharmaceuticals, Inc.
ETON's strategic focus on ultra-rare diseases and a portfolio of therapies for rare conditions aligns with the Biotech - Rare Diseases investable theme.
|
$671.51M |
$25.05
+2.52%
|
|
BIOA
BioAge Labs, Inc.
BioAge's lead program BGE-102 is an oral small-molecule therapeutic, and APJ agonists are being developed for obesity, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$662.96M |
$18.48
+8.77%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$656.25M |
$2.23
-0.22%
|
|
KE
Kimball Electronics, Inc.
KE's medical device and biometrics manufacturing capabilities are central to its strategy.
|
$652.51M |
$26.83
+1.48%
|
|
CMPS
COMPASS Pathways plc
Represents the company's focus on developing neuropsychiatric drugs in the CNS space.
|
$639.47M |
$6.66
-0.08%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$621.52M |
$2.00
+3.37%
|
|
SRDX
Surmodics, Inc.
Surmodics' vascular intervention devices (SurVeil DCB, Pounce thrombectomy, Sublime radial access) are a core product category sold by the company.
|
$614.58M |
$42.98
|
|
SIBN
SI-BONE, Inc.
SI-BONE operates as a medical device company that designs, develops and sells orthopedic implants and related medical devices.
|
$611.38M |
$14.11
+3.22%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$607.38M |
$7.40
-1.99%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's CF program (4D-710) targets a rare disease indication, aligning with the Rare Diseases Biotech theme.
|
$599.35M |
$10.50
+4.37%
|
Showing page 16 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
